论文部分内容阅读
目的:观察HELF方案联合干扰素治疗晚期胆囊癌的临床疗效和毒副反应。方法:24例晚期胆囊癌患者,应用HELF方案化疗,即HCPT6mg/m2、VP1660mg/m2、CF200mg/m2和5Fu500mg/m2,均为静脉滴注,第1～5天;其中前13例化疗同时给予α干扰素(αIFN)300万单位肌肉注射,1次/隔日,连用3个月以上,因药源性发热、骨髓抑制等毒副反应发生率较高,后11例患者更改为化疗结束后第2天给予αIFN300万单位肌肉注射,1次/日,连用10天。化疗每4周为1周期,2周期后按照WHO标准进行疗效及毒副反应评价。结果:24例均可以进行疗效评价,获得CR1例,PR5例,SD12例,PD6例,总有效率为25%,中位生存期17个月。毒副反应主要为骨髓抑制、脱发和药源性发热等。结论:HELF方案联合αIFN治疗晚期胆囊癌疗效较好,毒副反应小,患者耐受性好,序贯应用HELF方案及αIFN可以减轻毒副反应。
Objective: To observe the clinical efficacy and toxicity of HELF combined with interferon in the treatment of advanced gallbladder cancer. Methods: Twenty-four patients with advanced gallbladder cancer were treated with HELF regimen, ie HCPT 6mg / m2, VP1660mg / m2, CF200mg / m2 and 5Fu500mg / m2, Interferon α (IFNα) 3 million intramuscular injection, 1 / every other day, once every 3 months, due to drug-induced fever, bone marrow suppression and other toxic reactions were higher, after 11 patients changed to chemotherapy after the end of the first 2 days given αIFN 300 million units intramuscular injection, 1 / day, once every 10 days. Chemotherapy once every 4 weeks for 1 cycle, 2 cycles in accordance with WHO standards for efficacy and toxicity evaluation. Results: All of the 24 cases could be evaluated with CR1, PR5, SD12 and PD6. The total effective rate was 25% and the median survival time was 17 months. Toxicity mainly for bone marrow suppression, hair loss and drug-induced fever. Conclusions: HELF regimen combined with αIFN in the treatment of advanced gallbladder carcinoma has better curative effect, less toxic side effects and better patient tolerance. HELF regimen and αIFN can reduce the toxic and side effects.